KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Gains from Sales and Divestitures (2016 - 2021)

Resmed (RMD) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $704000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Gains from Sales and Divestitures fell 24.22% year-over-year to $704000.0, compared with a TTM value of $704000.0 through Jun 2021, down 24.22%, and an annual FY2021 reading of $704000.0, down 24.22% over the prior year.
  • Gains from Sales and Divestitures was $704000.0 for Q2 2021 at Resmed, down from $929000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $929000.0 in Q2 2020 and bottomed at $2911.0 in Q3 2018.
  • Average Gains from Sales and Divestitures over 5 years is $596515.5, with a median of $652065.0 recorded in 2018.
  • The sharpest move saw Gains from Sales and Divestitures crashed 68.56% in 2017, then skyrocketed 130.95% in 2019.
  • Year by year, Gains from Sales and Divestitures stood at $624617.0 in 2017, then surged by 41.95% to $886655.0 in 2018, then fell by 2.86% to $861256.0 in 2019, then increased by 7.87% to $929000.0 in 2020, then fell by 24.22% to $704000.0 in 2021.
  • Business Quant data shows Gains from Sales and Divestitures for RMD at $704000.0 in Q2 2021, $929000.0 in Q2 2020, and $915450.0 in Q1 2020.